Details for Patent: 7,762,994
✉ Email this page to a colleague
Which drugs does patent 7,762,994 protect, and when does it expire?
Patent 7,762,994 protects OZEMPIC, SAXENDA, and VICTOZA, and is included in three NDAs.
Protection for SAXENDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-two patent family members in thirteen countries.
Summary for Patent: 7,762,994
| Title: | Needle mounting system and a method for mounting a needle assembly |
| Abstract: | A needle mounting system and methods for mounting a needle assembly on a needle mount are disclosed. The needle mounting system includes a needle hub having protrusions extending radially inward. A needle mount has a plurality of slots to receive the protrusions. The slots have a first portion that defines a passageway substantially parallel to a longitudinal axis of the needle mount and a second portion substantially perpendicular to the axis. The needle hub and mount provide a method wherein a needle assembly may be mounted on an injection device without completely rotating the needle hub relative to the needle mount. |
| Inventor(s): | Klint; Henrik Sonderskov (Lyngby, DK), Radmer; Jim (Fredensborg, DK), Smedegaard; Jorgen K (Frederiksberg, DK), Nielsen; Jan Frank (Lyngby, DK), Jensen; Peter Moller (Horsholm, DK), Jensen; Jens Moller (Copenhagen, DK) |
| Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
| Application Number: | 11/778,274 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,762,994 |
|
Patent Claim Types: see list of patent claims | Device; |
Drugs Protected by US Patent 7,762,994
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-004 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-002 | Apr 9, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-003 | Mar 28, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,762,994
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Denmark | 2002 01169 | Aug 1, 2002 |
International Family Members for US Patent 7,762,994
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 344076 | ⤷ Try a Trial | |||
| Austria | 439883 | ⤷ Try a Trial | |||
| Australia | 2003243922 | ⤷ Try a Trial | |||
| Canada | 2491356 | ⤷ Try a Trial | |||
| China | 100502968 | ⤷ Try a Trial | |||
| China | 1665558 | ⤷ Try a Trial | |||
| Germany | 60309479 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
